The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

Amy Moran, Magdalena Kovacsovics-Bankowski, Andrew D. Weinberg

Research output: Contribution to journalReview article

90 Citations (Scopus)

Abstract

T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.

Original languageEnglish (US)
Pages (from-to)230-237
Number of pages8
JournalCurrent opinion in immunology
Volume25
Issue number2
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

Immunotherapy
T-Lymphocytes
Neoplasm Antigens
Neoplasms
Tumor Microenvironment
Tumor Necrosis Factor Receptors
Licensure
T-Cell Antigen Receptor
Immunity
Monoclonal Antibodies
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. / Moran, Amy; Kovacsovics-Bankowski, Magdalena; Weinberg, Andrew D.

In: Current opinion in immunology, Vol. 25, No. 2, 01.04.2013, p. 230-237.

Research output: Contribution to journalReview article

Moran, Amy ; Kovacsovics-Bankowski, Magdalena ; Weinberg, Andrew D. / The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. In: Current opinion in immunology. 2013 ; Vol. 25, No. 2. pp. 230-237.
@article{6d8dd47ffefd425699872e5144547845,
title = "The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy",
abstract = "T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.",
author = "Amy Moran and Magdalena Kovacsovics-Bankowski and Weinberg, {Andrew D.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.coi.2013.01.004",
language = "English (US)",
volume = "25",
pages = "230--237",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

AU - Moran, Amy

AU - Kovacsovics-Bankowski, Magdalena

AU - Weinberg, Andrew D.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.

AB - T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.

UR - http://www.scopus.com/inward/record.url?scp=84877059530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877059530&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2013.01.004

DO - 10.1016/j.coi.2013.01.004

M3 - Review article

C2 - 23414607

AN - SCOPUS:84877059530

VL - 25

SP - 230

EP - 237

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 2

ER -